Mark Trusheim is a Visiting Scientist at the MIT Sloan School of Management and the Strategic Director of the MIT Center for Biomedical Innovation’s NEWDIGS program. He is the Founder and President of Co-Bio Consulting, LLC and has been a Special Government Employee for the FDA’s Office of the Commissioner.
Mark’s research focuses on the economics of biomedical innovation, especially precision medicine, adaptive pathways, platform trials and their enablement by digital health advances. He also studies biotechnology regional clusters. His work emphasizes using quantitative modeling in multi-stakeholder processes to inform public policy, corporate strategy and product development and commercialization.
Prior to MIT, his career spanned big data and simulations at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Monsanto’s Cereon Genomics, molecular diagnostics as CEO of start-up Cantata Laboratories and policy as the President of the Massachusetts Biotechnology Council. Mark was a member of the Monsanto Pipeline Management Team and led the Monsanto Bioinformatics/IT activities.
Mark is a frequent invited speaker on precision medicine, companion diagnostics, adaptive pathways and regional life sciences development at international conferences. He holds degrees in Chemistry from Stanford University and Management (Finance and IT) from MIT.